Literature DB >> 23271772

Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.

Jenny L Donovan1.   

Abstract

Presenting treatment options to men with localized prostate cancer is difficult because of the lack of definitive evidence and the range of treatment options available. Active surveillance and monitoring programs are now a recognized treatment option for men with low-risk localized prostate cancer, but many patients are not fully aware of the details of such programs, and most still opt for immediate radical (surgery or radiotherapy) treatment. The provision of high-quality information with decision aids has been shown to increase the acceptability of active surveillance/monitoring programs. This chapter outlines techniques for providing high-quality information about active surveillance/monitoring, based on the findings of a randomized controlled trial of treatments for localized prostate cancer. The ProtecT (Prostate testing for cancer and Treatment) trial has randomized over 1500 men between active monitoring, radical surgery, and radical radiotherapy by ensuring that information was tailored to men's existing knowledge and views. Care was taken with the content, order, and enthusiasm of the presentation of treatments by recruitment staff, and clinicians and other health professionals were supported to feel comfortable with being open about the uncertainties in the evidence and helped to rephrase terminology likely to be misinterpreted by patients. These techniques of information provision should be added to the use of decision aids to enable patients diagnosed with clinically localized prostate cancer in routine practice to reach well-informed and reasoned decisions about their treatment, including full consideration of active surveillance and monitoring programs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271772      PMCID: PMC3540874          DOI: 10.1093/jncimonographs/lgs030

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  39 in total

1.  "You decide doctor". What do patient preference arms in clinical trials really mean?

Authors:  Ann Bowling; Gene Rowe
Journal:  J Epidemiol Community Health       Date:  2005-11       Impact factor: 3.710

2.  Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.

Authors:  J L Donovan; S J Frankel; A Faulkner; S Selley; D Gillatt; F C Hamdy
Journal:  BMJ       Date:  1999-01-30

Review 3.  Active surveillance for prostate cancer: for whom?

Authors:  Laurence Klotz
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

Review 4.  Watchful waiting for prostate cancer: a review article.

Authors:  G W Chodak; K S Warren
Journal:  Prostate Cancer Prostatic Dis       Date:  2006       Impact factor: 5.554

5.  Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.

Authors:  J E Johansson; L Holmberg; S Johansson; R Bergström; H O Adami
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

6.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

7.  Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer.

Authors:  Suzanne K Steginga; Stefano Occhipinti; R A Frank Gardiner; John Yaxley; Peter Heathcote
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

8.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

9.  Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).

Authors:  Jenny L Donovan; Tim J Peters; Sian Noble; Philip Powell; David Gillatt; Steven E Oliver; J Athene Lane; David E Neal; Freddie C Hamdy
Journal:  J Clin Epidemiol       Date:  2003-07       Impact factor: 6.437

Review 10.  Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

Authors:  Richard M Martin; David Gunnell; Freddie Hamdy; David Neal; Athene Lane; Jenny Donovan
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

View more
  10 in total

1.  Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer.

Authors:  Robert J Volk; Gianna T Kinsman; Yen-Chi L Le; Paul Swank; Jennifer Blumenthal-Barby; Stephanie L McFall; Theresa L Byrd; Patricia Dolan Mullen; Scott B Cantor
Journal:  J Health Commun       Date:  2015-06-11

2.  Treatment decisions for localized prostate cancer: a concept mapping approach.

Authors:  Stephanie L McFall; Patricia D Mullen; Theresa L Byrd; Scott B Cantor; Yen-Chi Le; Isabel Torres-Vigil; Curtis Pettaway; Robert J Volk
Journal:  Health Expect       Date:  2014-02-09       Impact factor: 3.377

3.  Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.

Authors:  Paola Dordoni; Sebastiaan Remmers; Riccardo Valdagni; Lara Bellardita; Letizia De Luca; Fabio Badenchini; Cristina Marenghi; Monique J Roobol; Lionne D F Venderbos
Journal:  BMC Urol       Date:  2022-07-18       Impact factor: 2.090

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

5.  Changing the Paradigm of Cancer Screening, Prevention, and Treatment.

Authors:  Mohan Doss
Journal:  Dose Response       Date:  2016-11-30       Impact factor: 2.658

6.  The effect of the area proportion of the metastatic lesion within the central metastatic lymph node on response to therapy in papillary thyroid carcinoma.

Authors:  Liuhong Shi; Liang Zhou; Jianbiao Wang; Lei Jin; Yinjiao Lei; Lian Xia; Lei Xie
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

7.  Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.

Authors:  Shellie D Ellis; Soohyun Hwang; Emily Morrow; Kim S Kimminau; Kelly Goonan; Laurie Petty; Edward Ellerbeck; J Brantley Thrasher
Journal:  BMC Cancer       Date:  2021-05-31       Impact factor: 4.430

Review 8.  Quality of Life and Psychological Distress among Patients with Small Renal Masses.

Authors:  Liliana Vartolomei; Andrei Cotruș; Camelia Stanciu; Cristian Delcea; Marco Tozzi; Elena Lievore; Felice Crocetto; Francesco Del Giudice; Giuseppe Lucarelli; Matteo Muto; Matteo Ferro
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

9.  Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Authors:  E L Turner; C Metcalfe; J L Donovan; S Noble; J A C Sterne; J A Lane; K N Avery; L Down; E Walsh; M Davis; Y Ben-Shlomo; S E Oliver; S Evans; P Brindle; N J Williams; L J Hughes; E M Hill; C Davies; S Y Ng; D E Neal; F C Hamdy; R M Martin
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

10.  Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.

Authors:  Ingrid J Hall; Judith Lee Smith
Journal:  Am J Prev Med       Date:  2015-12       Impact factor: 5.043

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.